TABLE 1.

Astrocyte transduction of AAV serotypes with pan-cellular promoters.

Study	Hammond et al., 2017	Harding et al., 2006 (mouse)	Harding et al., 2006 (glioma)	Schober et al., 2016	Klein et al., 2008	Wang et al., 2003	Howard et al., 2008	Royo et al., 2008	Hutson et al., 2012	Lawlor et al., 2009	Davidson et al., 2000	Liu et al., 2005
Model	In vivo	In vivo	Xenograft	In vivo/vitro	In vivo	In vivo	In vitro	In vitro	In vivo	In vivo	In vivo	In vivo
Promoter	CBA	CAG	CAG	CMV	CMV	CMV	CMV	CMV	CMV	CAG	RSV	RSV
1/AAV2 ITR	++			++		++	−^	+	++
2/2		+	++	++		+	−	++	+		+
3/2									−
4/2									−		−	++
5/2		++	++	++			++		++		++
6/2		+	++	+++			−^		++
7/2		+	++				−^	+
8/2	++*	+	++		++		−^	++	+	+
9/2	++*				−		−	++
rh43/2										+++

*, wild-type virus; ^, had transduced astrocytes 2 days after treatment. AAV, adeno-associated virus; CBA, CMV-Enhancer/Chicken β-Actin Promoter; CMV, Human Cytomegalovirus Immediate/Early Gene Promoter and Enhancer; CAG, Chicken β-Actin/Cytomegalovirus Hybrid Promoter; RSV, Rous Sarcoma Virus Long Terminal Repeat Promoter.